Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have received an average rating of “Moderate Buy” from the seventeen research firms that are covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $55.06.

A number of brokerages have recently weighed in on KYMR. UBS Group lowered their price target on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Stephens reaffirmed an “overweight” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research note on Tuesday. Guggenheim increased their price target on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. Leerink Partners reaffirmed an “outperform” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research report on Friday, December 27th. Finally, BMO Capital Markets began coverage on shares of Kymera Therapeutics in a research report on Friday, December 6th. They issued a “market perform” rating and a $55.00 target price for the company.

Insider Activity

In related news, insider Ellen Chiniara sold 3,129 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $41.75, for a total transaction of $130,635.75. Following the transaction, the insider now owns 54,826 shares of the company’s stock, valued at approximately $2,288,985.50. The trade was a 5.40 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 15.82% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Blue Trust Inc. increased its position in Kymera Therapeutics by 74.8% during the fourth quarter. Blue Trust Inc. now owns 631 shares of the company’s stock worth $25,000 after acquiring an additional 270 shares during the period. Values First Advisors Inc. bought a new position in Kymera Therapeutics during the third quarter worth $61,000. KBC Group NV boosted its stake in Kymera Therapeutics by 53.8% during the fourth quarter. KBC Group NV now owns 2,151 shares of the company’s stock worth $87,000 after buying an additional 752 shares in the last quarter. Quarry LP acquired a new stake in Kymera Therapeutics during the third quarter worth $95,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in Kymera Therapeutics by 27.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock worth $114,000 after buying an additional 504 shares in the last quarter.

Kymera Therapeutics Trading Up 1.0 %

Shares of KYMR opened at $44.13 on Thursday. The business’s 50-day moving average price is $42.71 and its 200 day moving average price is $44.65. The stock has a market capitalization of $2.86 billion, a P/E ratio of -18.86 and a beta of 2.19. Kymera Therapeutics has a 1-year low of $29.24 and a 1-year high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The business had revenue of $3.74 million for the quarter, compared to analyst estimates of $10.34 million. During the same quarter in the previous year, the business earned ($0.90) earnings per share. The firm’s revenue was down 20.9% compared to the same quarter last year. On average, research analysts predict that Kymera Therapeutics will post -2.79 earnings per share for the current year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.